Table: Santen Pharm -2019/20 group results (IFRS)
08/05/2020 07:00
May 8 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2020 Mar 31, 2019 Mar 31, 2021 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULT FORECAST H1 FORECAST
Sales 241.56 234.03 235.00
(+3.2 pct) (+4.0 pct) (-2.7 pct)
Operating 33.54 45.10 35.00
(-25.6 pct) (+16.6 pct) (+4.4 pct)
Pretax 32.09 43.12 34.00
(-25.6 pct) (+9.8 pct) (+5.9 pct)
Net 23.62 31.95
(-26.1 pct) (-9.3 pct)
EPS Basic 59.16 yen 78.67 yen 58.35 yen
EPS Diluted 59.01 yen 78.43 yen
Ann Div 27.00 yen 26.00 yen 28.00 yen
-Q2 Div 13.00 yen 13.00 yen 14.00 yen
-Q4 Div 14.00 yen 13.00 yen 14.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T